PIK3CA mutations and subsequent activation of the AKT pathway play a crucial role in human neoplasms. PIK3CA mutations have been associated with poor prognosis in patients with colorectal or lung cancer. In contrast, the relationship between PIK3CA mutations and favorable prognoses has been shown in breast cancer. However, no large-scale study has examined the prognostic impact of PIK3CA mutations in esophageal squamous cell carcinoma (ESCC). In this study, we quantified the PIK3CA mutations in exons 9 and 20 using a non-biased database of 219 curatively resected ESCCs and pyrosequencing technology. This is, by far, the largest study on the prognostic role of PIK3CA mutations in ESCC to date, and it shows that PIK3CA mutations in ESCC are associated with favorable prognoses. Our data suggest that PIK3CA mutational status can have a potential role as a prognostic biomarker. on November 12, 2017.
INTRODUCTION
Esophageal squamous cell carcinoma (ESCC), the major histological type of esophageal cancer in East Asian countries, is one of the most aggressive malignant tumors (1) .
Despite the development of multimodality therapies, the prognosis of patients remains poor, even for those who undergo complete resection of their carcinomas (2) (3) (4) . The limited improvement in treatment outcome provided by conventional therapies has prompted us to seek innovative strategies for treating ESCCs, especially those that are molecularly-targeted. The identification of new prognostic or predictive molecular markers for ESCC may improve the risk-adapted therapeutic strategies and help stratify patients in future clinical trials for treatment with drugs targeting these molecular changes (5, 6) .
Activation of the phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway plays an important role in the development of a variety of human carcinomas, and several efforts are underway to define therapeutic inhibitors of this signaling pathway (7, 8) . PI3K interacts with phosphatidylinositol-3-phosphate at the membrane and catalyzes the phosphorylation of AKT, which activates the downstream signaling pathway (8) .
Mutations in the PIK3CA gene, which encodes the p110α catalytic subunit of PI3K (7, 8) , have been identified in many human cancers (9) . The majority of activating PIK3CA mutations map to 3 sites (codons 542 and 545 in exon 9 and codon 1,047 in exon 20) (10) . In studies of ESCC, PIK3CA mutation has been detected in 2.2% to 11.8% of analyzed cases (11) (12) (13) (14) , and its prognostic role has been still unknown. Previous studies in large numbers of cases (more than 200) have shown that PIK3CA mutations are associated with unfavorable prognosis in patients with colorectal (15) (16) (17) (18) (19) or lung cancer To test this hypothesis, we quantified the PIK3CA mutations in 219 samples of curatively resected ESCCs using pyrosequencing, and examined the prognostic significance of PIK3CA mutations in ESCC. In addition, we also evaluated the relationship between PIK3CA mutations, phosphorylated AKT (p-AKT) expression, which was the most successful biomarker for evaluating the status of AKT activation, and p53 expression, which was one of the important molecular alterations in ESCC.
METHODS

Study subjects
A total of 235 patients with ESCC who underwent curative resection at Kumamoto University Hospital between April 2005 and December 2011 were enrolled in this study.
Fifteen patients were excluded because of the unavailability of adequate tissue samples.
We initially quantified PIK3CA mutations in 220 cancer specimens, and obtained valid results in 219 (99.5%) of the cases. Thus, a total of 219 ESCCs were ultimately included in this study. Patients were observed at 1-to 3-month intervals until death or 31 March 2012, whichever came first. Tumor staging was performed by the American Joint Committee on Cancer Staging Manual (7th edition) (22 Disease-free survival was defined as the length of time after surgical treatment of the cancer during which the patient survived with no sign of cancer recurrence. Overall survival was defined as the time between the date of the operation and the date of death.
Cancer-specific survival was defined as the time between the date of operation and the date of death, which was confirmed to be attributable to ESCC. In our cohort, the 5-year overall survival rates of patients treated by esophagectomy were 83.9% for stage I, 59.7% for stage II, and 36.7% for stage III. These rates were comparable with those from the "Comprehensive Registry of Esophageal Cancer in Japan" (79.5% for stage I, 58.9% for stage II, and 39.8% for stage III), certainly supporting the absence of bias in our database. Written informed consent was obtained from each subject, and the study procedures were approved by the institutional review board. The term "prognostic marker" is used throughout this article according to the REMARK Guidelines (23) .
Cell Lines
The TE-1, TE-4, TE-8, TE-9, TE-11, TE-14, TE-15 (obtained from the Institute of Development, Aging, and Cancer, Tohoku University) and KYSE30 (obtained from Japanese Collection Research Bioresources, Japan) human esophageal cancer cell lines were cultured in a medium supplemented with 10% fetal bovine serum in 5% CO 2 atmosphere at 37°C.
Genomic DNA Extraction
Research. Genomic DNA was extracted from 220 paraffin-embedded tissue specimens of surgically resected esophageal cancers. Tumors areas were marked on hematoxylin-eosin stained slides by one pathologist (Y.B). Genomic DNA was extracted from tumor lesions enriched with neoplastic cells, without adjacent normal tissue, using an FFPE kit (Qiagen, Valencia, CA). DNA was also extracted from ESCC cell lines using a QIAmp DNA mini kit (Qiagen).
Pyrosequencing for PIK3CA mutations
The exon 9 PCR primers were as follows: 
Statistical methods
For the statistical analyses, we used the JMP (Version 9, SAS Institute, Cary, NC) and the SAS software programs (Version 9.1, SAS Institute). All P values were two-sided.
For the survival analysis, the Kaplan-Meier method was used to assess the survival time distribution, and the log-rank test was used. To assess the independent effect of the PIK3CA mutations on mortality, the tumor stage (IA+IB, IIA+IIB, IIIA+IIIB+IIIC) was used as a stratifying (matching) variable in Cox models using the "strata" option in the SAS "proc phreg" command to avoid residual confounding and overfitting. We constructed a multivariate, stage-stratified Cox proportional hazard model to compute a hazard ratio 
RESULTS
PIK3CA mutational status in ESCC
Among 219 patients who had undergone curative resection of stage I to III ESCC, we examined PIK3CA exon 9 and 20 mutations by pyrosequencing technology (Figure 1 ).
PIK3CA mutations were detected in 46 (21%) of 219 cases; 11 cases in exon 9 only, 21 cases in exon 20 only, and 14 cases in both exon 9 and 20. The most common mutation was the c.3140A>G (p.H1047R) mutation, which was present in 35 tumors, followed by c.1633G>A (p.E545K) in 16 tumors (Supplementary Table 1 
PIK3CA mutations and patients characteristics
PIK3CA mutations were significantly associated with p-AKT expression (P=0.0043). In contrast, there was no significant relationship between PIK3CA mutations and p53 expression. PIK3CA mutations were not significantly associated with any clinical, epidemiological or pathological characteristics (Table 2) .
PIK3CA mutations and patient survival
We assessed the influence of PIK3CA mutations on clinical outcome in patients with curatively resected ESCC. During the follow-up of the 219 patients, there were a total of 71 esophageal cancer recurrences, 70 deaths, and 52 deaths confirmed to be attributable to esophageal cancer. The median follow-up time for censored patients was 2.2 years.
In the Kaplan-Meier analysis, patients with PIK3CA mutations experienced significantly longer disease-free survival (log rank P=0.0089), cancer-specific survival (log rank P=0.021), and overall survival (log rank P=0.012) than those with wild-type PIK3CA (Figure 2 We also assessed PIK3CA exon 9 mutations and exon 20 mutations separately.
However, there was no significant difference in mortality between exon 9 and exon 20 mutations (log rank P=0.59). In addition, patients with concomitant PIK3CA mutations in exons 9 and 20 experienced a similar prognosis with those with PIK3CA mutation in either exon 9 or 20 alone (log rank P=0.98) (Supplementary figure 2) .
Survival analyses of the interaction between PIK3CA mutations and other variables
We also examined whether the influence of PIK3CA mutations on cancer-specific survival was modified by any of the clinical, pathological and epidemiological variables evaluated. The effect of PIK3CA mutations was not significantly modified by tobacco use, alcohol use, year of diagnosis, tumor grade, or tumor stage (all P>0.29; Figure 3) .
Survival analyses for patients with or without preoperative therapy
Research. 
The relationship between preoperative chemotherapy and/or radiotherapy and PIK3CA mutation is not known. Therefore, we performed the additional survival analyses for two subgroups; one is a cohort without preoperative therapy (n=137) and another is a cohort with preoperative treatment (n=82). Patients with PIK3CA mutations experienced better disease-free survival compared with wild-type PIK3CA cases both in cohort without preoperative treatment (log rank P=0.080, univariate HR=0.41, 95% CI 0.12-1.03, P=0.058) and cohort with preoperative treatment (log rank P=0.064, univariate HR=0.34, 95% CI 0.083-0.96, P=0.041) (Supplementary figure 3) . Notably, we did not observe a modifying effect of the preoperative treatment on the relationship between PIK3CA mutation and the recurrence rate (P for interaction = 0.76, Figure 3 ),
DISCUSSION
PIK3CA mutations and subsequent activation of the AKT pathway are considered to play a crucial role in human neoplasms (24) (25) (26) . The PI3K/AKT pathway has emerged as a central node in cancer cell signaling pathways downstream of growth factors, cytokines, and other cellular stimuli (7, 8) . We conducted this study to examine the prognostic impact of PIK3CA mutations among 219 patients with curatively resected esophageal squamous cell carcinomas (ESCCs). We found that PIK3CA mutations in ESCCs are associated with a good prognosis, suggesting that PIK3CA mutational status may be a biomarker that can be used to identify patients who will experience a favorable clinical outcome.
Examining biomarkers or prognostic factors is important in cancer research (27-31).
Previous studies examining the relationship between PIK3CA mutations and prognosis in human cancers have yielded variable results (Table 1 ; all n≥200). In addition, the relationship between PIK3CA mutations and a better prognosis has been demonstrated in several small-sized studies (all n < 200) of breast cancer and ovarian cancer (32-35).
This discrepancy might be due to differences in the tumor histological type. A study of ESCC showed that PIK3CA mutational status is not associated with patient survival; however, this study was limited by its small sample size (n=87) (11) . The importance of large-scale studies cannot be emphasized enough, because small studies with null results have much higher likelihood of being unpublished than small studies with "significant" results, leading to publication bias. In contrast to the previous study, our study examined PIK3CA mutational status in a much larger non-biased cohort of ESCCs.
Nonetheless, our finding of the correlation between PIK3CA mutations and favorable prognosis in esophageal cancer needs to be confirmed by independent studies in the future.
We also found the significant relationship between PIK3CA mutation and p-AKT expression (i.e., AKT activation) in ESCCs. This finding is in agreement with previous results on colorectal cancer, bladder cancer, and pancreas neoplasms (36-38). There was no perfect correlation between PIK3CA mutation and p-AKT, in part because there were other mechanisms of AKT activation (i.e., PTEN loss and/or methylation, PIK3CA amplification, and PIK3RI mutation). Given the well-known roles of the AKT pathway in tumor proliferation, invasion, and survival (8, (39) (40) (41) , one could expect that PIK3CA mutations would imply poor clinical outcome. It is very common to assume that the (44, 45) . In addition, one study on colorectal cancer reported that p-AKT expression is associated with low stage cancer and good prognosis (36). Future studies are necessary to elucidate the biological mechanisms by which PIK3CA mutation activation affects esophageal cancer behavior.
Interestingly, we detected PIK3CA mutations in 21% of ESCCs. This frequency is slightly higher compared with those of previous studies on ESCCs. This difference might be due to a difference in the patient cohorts or the methods used to assess PIK3CA mutation. In the current study, we used pyrosequencing, which has been shown to be Pyrosequencing is a non-electrophoretic nucleotide extension sequencing technology that can be used for mutation detection in tumors. Pyrosequencing assay for PIK3CA mutation detection is certainly useful, because most activating PIK3CA mutations cluster in the hotspots of exons 9 and 20, affecting the functionally important helical and kinase domains.
In summary, our large cohort study suggests that PIK3CA mutations are associated with a favorable clinical outcome in stage I to III esophageal cancer, supporting its role as a prognostic biomarker. Future studies are needed to confirm this association, and to elucidate the exact mechanisms by which PIK3CA mutation affects tumor behavior.
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Table1. Studies on prognostic significance of PIK3CA mutations in several types of cancers Abbreviations: CS, cancer-specific survival; DFS; disease-free survival; LR, local recurrence; N/A, not available; OS, overall survival; PFS, progression-free survival; RFS, relapse-free survival. 
